Zhejiang to distribute T-Line technology in certain Asian markets


Tensys Medical has entered into a commercial agreement with Zhejiang Shanshi Medical Device Co for distribution of the company's T-Line technology. The agreement will permit Shanshi to market, pending final regulatory approvals, the company's latest TL-300 throughout China, Taiwan and Hong Kong. Under terms of the five year exclusive supply relationship, the parties have agreed on cumulative orders of up to US$40 million.

Shanshi will initially target T-line into the Chinese operating room and intensive care unit markets. The T-Line technology platform accurately and continuously captures a patient's beat-to-beat waveform and blood pressure in a completely non-invasive fashion, providing physicians with a stream of real-time haemodynamic data that is not possible using traditional non-invasive cuffed blood pressure devices. Avoiding the blind-time associated with a deflated or inaccurate cuff can enhance haemodynamic monitoring, which has been definitively linked to improved clinical outcomes.

The latest-generation TL-300 features a tablet supported monitor that allows touch-screen control and displays a patient's key haemodynamic parameters. In addition to above features, the operator is readily able to view trend data for up to a 12-hour period. The tablet displays data coming from an integrated bracelet, sensor and wrist frame placed over the patient's radial artery. The wrist frame is disposed at the end of the case and the bracelet and sensor are immediately available for the next patient.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: China, China, Hong Kong, Taiwan, China, China